Bd reports second quarter fiscal 2022 financial results

Revenue of $5.0 billion increased 2.1% as reported and 3.9% on currency-neutral basis revenue driven by base revenue growth of 8.2% as reported, 10.2% currency-neutral, partially offset by decline in worldwide covid-only testing revenues to $214 million from $474 million in the prior year gaap diluted eps of $1.50; adjusted diluted eps of $3.18 company raises mid-point of revenue and adjusted eps guidance ranges; adjusts for completed spin of diabetes care business franklin lakes, n.j., may 5, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its second quarter of fiscal year 2022, which ended march 31, 2022.
BDX Ratings Summary
BDX Quant Ranking